In this poster, we describe our methodology for calculating TMB, which considers an estimation of true germline mutations and the identification of regions within a capture panel that most reliably contribute to robust TMB scoring.
In addition, we introduce a method to determine the effect on TMB scores when in silico determination of germline variants is used to derive somatic calls when matching normal samples are not available. Defining the robustness of this score across and criteria for its derivation will help better position defining analytical range and future utility across indications and NGS panels.
Wendell Jones, Ph.D., Principal Bioinformaticist and Scientific Advisor
Victor Weigman, Ph.D., Director, Translational Genomics